July 7, 2014

Helix BioPharma Corp Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company’s expanding clinical trial initiatives.